WEBULL
News
VTVT
35.14
+10.99%
3.48
Weekly Report: what happened at VTVT last week (0202-0206)?
Weekly Report · 2d ago
Analysts Are Bullish on These Healthcare Stocks: vTv Therapeutics (VTVT), Acumen Pharmaceuticals (ABOS)
TipRanks · 02/03 02:40
vTv Therapeutics Expands Global HPP737 Rights with Newsoara
TipRanks · 02/02 21:58
vTv Therapeutics LLC schließt erweiterten Lizenzvertrag mit Newsoara Biopharma ab
Reuters · 02/02 21:19
vTv LLC Expands Global Rights of HPP737 to Newsoara for $20 Million Upfront
Reuters · 02/02 21:19
Analysts Are Bullish on Top Healthcare Stocks: Pelthos Therapeutics (PTHS), Twist Bioscience (TWST)
TipRanks · 02/02 18:30
vTv Therapeutics Expands License Deal With Newsoara Biopharma To Offer Global Rights To PDE4 Inhibitor
Benzinga · 02/02 13:23
vTv Therapeutics expanded its license agreement with Newsoara Biopharma
TipRanks · 02/02 13:15
vTv Therapeutics Expands License Agreement With Newsoara Biopharma for Global Rights to HPP737
Reuters · 02/02 13:03
VTV THERAPEUTICS INC - TO RECEIVE $20 MLN UPFRONT PAYMENT FROM NEWSOARA
Reuters · 02/02 13:00
VTV THERAPEUTICS INC - AMENDED LICENSE INCLUDES $50 MLN DEVELOPMENT AND $65 MLN SALES MILESTONES
Reuters · 02/02 13:00
Weekly Report: what happened at VTVT last week (0126-0130)?
Weekly Report · 02/02 09:02
VTV THERAPEUTICS INC <VTVT.O>: BTIG RAISES TARGET PRICE TO $49 FROM $40
Reuters · 01/27 11:17
vTv Therapeutics Is Maintained at Buy by BTIG
Dow Jones · 01/27 11:17
vTv Therapeutics Price Target Raised to $49.00/Share From $40.00 by BTIG
Dow Jones · 01/27 11:17
BTIG Maintains Buy on vTv Therapeutics, Raises Price Target to $49
Benzinga · 01/27 11:07
U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings
Reuters · 01/27 07:49
Weekly Report: what happened at VTVT last week (0119-0123)?
Weekly Report · 01/26 09:02
Analysts’ Top Healthcare Picks: OKYO Pharma Limited Sponsored ADR (OKYO), vTv Therapeutics (VTVT)
TipRanks · 01/23 17:21
More
Webull provides a variety of real-time VTVT stock news. You can receive the latest news about Vtv Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.